Tiainen, Satu
Nurmela, Veera
Selander, Tuomas
Turunen, Patrik
Pasonen-Seppänen, Sanna
Kettunen, Tiia
Kuittinen, Outi
Auvinen, Päivi
Rönkä, Aino http://orcid.org/0000-0001-6007-3648
Funding for this research was provided by:
Syöpäsäätiö
Suomen Lääketieteen Säätiö
The Northern Savo Cancer Foundation
Article History
Received: 16 June 2023
Accepted: 30 November 2023
First Online: 4 December 2023
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki. Ethical approval of the study was obtained from the Medical Research Ethics Committee of Wellbeing Services County of North Savo (permission number 1482/2019) and organization-level permission from Kuopio University Hospital (research permit 5654210, 916/2022). Due to the retrospective nature of the study, the Medical Research Ethics Committee of Wellbeing Services County of North Savo waived the informed consent requirement (permission number 1482/2019).
: Not applicable.
: ST has received personal fees for speaking at symposia, participating in advisory boards and consulting, and financial support for attending conferences from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, MSD, Merck, Novartis, Pfizer, Roche and Sanofi Genzyme. TK reports personal fees or financial support for attending conferences from AbbVie, Amgen, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, MSD, Novartis, Pfizer, Pierre Fabre, Roche and Sobi. AR reports personal fees for speaking at symposia or financial support for attending conferences from Amgen, Bristol-Myers Squibb, Merck, Novartis, Pfizer and Roche. None of the financial support was related to the present study. All other authors declare that they have no competing interests.